Patents by Inventor Kaoru Shimada

Kaoru Shimada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210213421
    Abstract: An object of the present invention is to provide a carrier for adsorbing organic matter, which achieves both of adsorption ability for organic matter and suppression of pressure increase. The present invention provides a carrier for adsorbing organic matter, comprising a sea-island type solid composite fiber, wherein the pore volume is 0.05 to 0.5 cm3/g and the fiber diameter is 25 to 60 ?m.
    Type: Application
    Filed: July 5, 2019
    Publication date: July 15, 2021
    Applicant: TORAY INDUSTRIES, INC.
    Inventors: Shungo KANDA, Kaoru SHIMADA, Shunsuke KOMACHI, Hiroshi TAKAHASHI, Hirofumi YAMANAKA, Masato MASUDA
  • Publication number: 20210179613
    Abstract: The present invention relates to use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, for the manufacture of a medicament for the treatment of cachexia. The invention also relates to a method for the treatment of cachexia, comprising administering the compound of the present invention or a pharmaceutical composition comprising the same to a human or an animal. The invention further relates to use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, in combination with one or more second active agents. Moreover, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, for the treatment of said disease.
    Type: Application
    Filed: March 2, 2021
    Publication date: June 17, 2021
    Applicant: RaQualia Pharma Inc.
    Inventors: Kaoru SHIMADA, Masaki SUDO, Masaomi TAJIMI, Nobuyuki TAKAHASHI, Kazuhiko NONOMURA
  • Patent number: 10975070
    Abstract: The present invention relates to use of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, for the manufacture of a medicament for the treatment of cachexia. The invention also relates to a method for the treatment of cachexia, comprising administering the compound of the present invention or a pharmaceutical composition comprising the same to a human or an animal. The invention further relates to use of said compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt, in combination with one or more second active agents. Moreover, the invention relates to a pharmaceutical composition and a kit comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, for the treatment of said disease.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: April 13, 2021
    Assignee: RaQualia Pharma Inc.
    Inventors: Kaoru Shimada, Masaki Sudo, Masaomi Tajimi, Nobuyuki Takahashi, Kazuhiko Nonomura
  • Publication number: 20210086166
    Abstract: An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.
    Type: Application
    Filed: December 7, 2020
    Publication date: March 25, 2021
    Applicant: TORAY INDUSTRIES, INC.
    Inventors: Naotoshi TOMITA, Kaoru SHIMADA, Hiroshi TAKAHASHI
  • Patent number: 10888840
    Abstract: An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: January 12, 2021
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Naotoshi Tomita, Kaoru Shimada, Hiroshi Takahashi
  • Publication number: 20200197594
    Abstract: An object of the present invention is to provide a material which can remove an activated leukocyte-activated platelet complex with high efficiency. The present invention provides a material for removing an activated leukocyte-activated platelet complex, the material being a water-insoluble carrier to the surface of which carrier a compound(s) having a charged functional group(s) is(are) bound, wherein an extending length ratio of the surface is 4 to 7.
    Type: Application
    Filed: June 6, 2018
    Publication date: June 25, 2020
    Applicant: TORAY INDUSTRIES, INC.
    Inventors: Naotoshi TOMITA, Kaoru SHIMADA, Hiroshi TAKAHASHI
  • Publication number: 20200010320
    Abstract: Provided are sodium hypochlorite pentahydrate crystals capable of long-term storage that have improved stability of sodium hypochlorite pentahydrate, which is effective as an oxidizing agent or bactericide, in the vicinity of normal temperatures, and a method for producing the same. The sodium hypochlorite pentahydrate crystals are such that peaks appear at the locations of the angles of diffraction described in Table 1 of claim 1 over a range of 10°?2? (angle of diffraction)?65° as measured by powder X-ray diffraction using a CuK? radiation source.
    Type: Application
    Filed: February 6, 2018
    Publication date: January 9, 2020
    Inventors: Tomohide OKADA, Hideo SHIMAZU, Hiromichi ITO, Yukihiro SUGIYAMA, Takashi TOYAMA, Kaoru SHIMADA, Hiroshi FUJIHISA, Satoshi TAKEYA, Takehiro MATSUNAGA, Yoshito GOTOH
  • Publication number: 20190367360
    Abstract: Provided are sodium hypochlorite pentahydrate crystal gains that have high bulk density and increase bulk density in a container and improve transport efficiency by controlling the shape of the sodium hypochlorite pentahydrate crystals, and a production method thereof. As a result of stirring or circulating by pump an aqueous solution of sodium hypochlorite pentahydrate in a crystallization tank in a crystallization step, sodium hypochlorite pentahydrate crystal grains are obtained having an average aspect ratio of 2.5 or less.
    Type: Application
    Filed: January 30, 2018
    Publication date: December 5, 2019
    Inventors: Hideo SHIMAZU, Tomohide OKADA, Tomotake ASAWA, Hiromichi ITO, Yukihiro SUGIYAMA, Kaoru SHIMADA
  • Patent number: 9937440
    Abstract: An adsorption carrier-packed column includes a central pipe, adsorption carrier, plate A, and plate B, wherein an insertion material C is inserted between the adsorption carrier and the plate A; an insertion material D is inserted between the adsorption carrier and the plate B; the ratio of the deformation rate of the insertion material C (C1) to the deformation rate of the adsorption carrier (E0) is 1<C1/E0<10, and the ratio of the deformation rate of the insertion material D (D1) to the deformation rate of the adsorption carrier (E0) is 1<D1/E0<10; and the ratio of the thickness of the insertion material C (TC) to the distance of a gap between the adsorption carrier and the plate A (LA) is 1.1<TC/LA<4, and the ratio of the thickness of the insertion material D (TD) to the distance of a gap between the adsorption carrier and the plate B (LB) is 1.1<TD/LB<4.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: April 10, 2018
    Assignee: Toray Industries, Inc.
    Inventors: Naotoshi Tomita, Kaoru Shimada, Yoshiyuki Ueno
  • Patent number: 9901571
    Abstract: The present invention relates to novel compounds of a formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions comprising them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR-1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: February 27, 2018
    Assignee: RaQualia Pharma Inc.
    Inventors: Yasuhiro Iwata, Kiyoshi Kawamura, Masaki Sudo, Kaoru Shimada, Shinichi Koizumi, Nobuyuki Takahashi, Keiko Obata, Makiko Kuroda
  • Patent number: 9873695
    Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: January 23, 2018
    Assignee: RaQualia Pharma Inc.
    Inventors: Yasuhiro Iwata, Kiyoshi Kawamura, Masaki Sudo, Kaoru Shimada, Shinichi Koizumi, Nobuyuki Takahashi, Keiko Obata, Makiko Kuroda
  • Patent number: 9833447
    Abstract: This invention relates to 4-{[4-({([4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]-oxy}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid for use in therapeutic treatment of the human body. In particular, it relates to the compound having selective 5-HT4 receptor agonism, which is useful for treating gastroparesis, or preventing or delaying the onset or the progression of gastroparesis.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: December 5, 2017
    Assignee: RAQUALIA PHARMA INC.
    Inventors: Nobuyuki Takahashi, Toshinori Yamamoto, Kaoru Shimada, Hirohide Noguchi
  • Publication number: 20170304277
    Abstract: The present invention relates to novel compounds of a formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions comprising them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR-1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.
    Type: Application
    Filed: November 2, 2015
    Publication date: October 26, 2017
    Applicant: RaQualia Pharma Inc.
    Inventors: Yasuhiro IWATA, Kiyoshi KAWAMURA, Masaki SUDO, Kaoru SHIMADA, Shinichi KOIZUMI, Nobuyuki TAKAHASHI, Keiko OBATA, Makiko KURODA
  • Publication number: 20170197961
    Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSRla receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.
    Type: Application
    Filed: August 5, 2015
    Publication date: July 13, 2017
    Applicant: RaQualia Pharma Inc.
    Inventors: Yasuhiro IWATA, Kiyoshi KAWAMURA, Masaki SUDO, Kaoru SHIMADA, Shinichi KOIZUMI, Nobuyuki TAKAHASHI, Keiko OBATA, Makiko KURODA
  • Publication number: 20170056387
    Abstract: This invention relates to 4-{[4-({([4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]-oxy}methyppiperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid for use in therapeutic treatment of the human body. In particular, it relates to the compound having selective 5-HT4 receptor agonism, which is useful for treating gastroparesis, or preventing or delaying the onset or the progression of gastroparesis.
    Type: Application
    Filed: May 18, 2015
    Publication date: March 2, 2017
    Inventors: Nobuyuki Takahashi, Toshinori Yamamoto, Kaoru Shimada, Hirohide Noguchi
  • Patent number: 9522140
    Abstract: The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blocker such as NaV1.3 and NaV1.7, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: December 20, 2016
    Assignee: RAQUALIA PHARMA INC.
    Inventors: Tadashi Inoue, Shuzo Watanabe, Tatsuya Yamagishi, Yoshimasa Arano, Mikio Morita, Kaoru Shimada
  • Patent number: 9499543
    Abstract: The present invention relates to novel crystal forms of 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide L-tartrate. More particularly, the invention relates to polymorph forms, and to processes for the preparation of compositions containing and to uses of such polymorph forms.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: November 22, 2016
    Assignee: RaQualia Pharma Inc.
    Inventors: Masaki Sudo, Kaoru Shimada, Hiroaki Wakabayashi, Toyoharu Numata
  • Patent number: 9447096
    Abstract: The present invention relates to novel crystal forms of 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide L-tartrate. More particularly, the invention relates to polymorph forms, and to processes for the preparation of compositions containing and to uses of such polymorph forms.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: September 20, 2016
    Assignee: RaQualia Pharma Inc.
    Inventors: Masaki Sudo, Kaoru Shimada, Hiroaki Wakabayashi, Toyoharu Numata
  • Patent number: 9447065
    Abstract: The present invention provides a pharmaceutical composition which prevents from decreasing the blood exposure of the third generation coxib-drugs, a process for preparing the said pharmaceutical composition and its use. It has been founded in this invention that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can afford a pharmaceutical composition which can prevent from decreasing the blood exposure, AUC and bioavailability. The pharmaceutical composition of the present invention has also good stability, which is useful for drugs. Namely, the technological thought that adding a basic amine or a basic amino acid, or a cyclodextrin to the third generation coxib-drug can prevent from decreasing the blood exposure, AUC and bioavailability has been established in this invention.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: September 20, 2016
    Assignee: RaQualia Pharma Inc.
    Inventors: Yasuhiro Iwata, Kaoru Shimada, Yoshiyuki Okumura, Mayumi Kashino, Hiromitsu Yoshida
  • Publication number: 20160107100
    Abstract: An adsorption carrier-packed column includes a central pipe, adsorption carrier, plate A, and plate B, wherein an insertion material C is inserted between the adsorption carrier and the plate A; an insertion material D is inserted between the adsorption carrier and the plate B; the ratio of the deformation rate of the insertion material C (C1) to the deformation rate of the adsorption carrier (E0) is 1<C1/E0<10, and the ratio of the deformation rate of the insertion material D (D1) to the deformation rate of the adsorption carrier (E0) is 1<D1/E0<10; and the ratio of the thickness of the insertion material C (TC) to the distance of a gap between the adsorption carrier and the plate A (LA) is 1.1<TC/LA<4, and the ratio of the thickness of the insertion material D (TD) to the distance of a gap between the adsorption carrier and the plate B (LB) is 1.1<TD/LB<4.
    Type: Application
    Filed: May 30, 2014
    Publication date: April 21, 2016
    Inventors: Naotoshi Tomita, Kaoru Shimada, Yoshiyuki Ueno